New insider activity at Jazz Pharmaceuticals ( (JAZZ) ) has taken place on December 11, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mary Elizabeth Henderson, the Senior Vice President of Technical Operations at Jazz Pharmaceuticals, recently sold 2,238 shares of the company’s stock. This transaction was valued at $379,363.
Recent Updates on JAZZ stock
Jazz Pharmaceuticals has seen significant positive developments recently, primarily driven by the favorable results from the HERIZON-GEA-01 study, which evaluated the bispecific HER2-directed antibody zanidatamab in HER2+ advanced/metastatic gastroesophageal adenocarcinoma. This has led multiple analysts to adjust their price targets upwards. Piper Sandler raised its target due to a reduced risk adjustment in sales estimates, while UBS, despite a downgrade to Neutral, acknowledged the improved outlook but noted that the recent stock surge reflects the oncology momentum. Truist and BofA also increased their targets, citing the promising potential of Ziihera, a drug with significant market prospects in HER2+ cancers. Baird’s adjustment was based on the study’s results being a best-case scenario, further supporting the stock’s upward trajectory.
Spark’s Take on JAZZ Stock
According to Spark, TipRanks’ AI Analyst, JAZZ is a Neutral.
Jazz Pharmaceuticals’ overall score is driven by strong earnings call results and positive corporate events, indicating strategic growth potential. However, financial performance challenges and valuation concerns weigh on the score.
To see Spark’s full report on JAZZ stock, click here.
More about Jazz Pharmaceuticals
YTD Price Performance: 33.30%
Average Trading Volume: 1,002,931
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.86B